Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07272434 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 9, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response.
Trial Details
NCT Number NCT07272434
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Collaborators: Henan Center for Disease Control and Prevention, Hunan Provincial Center for Disease Control and Prevention, Hubei Provincial Center for Disease Control and Prevention, Shaanxi Provincial Center for Disease Control and Prevention, Guangdong Center for Disease Prevention and Control, Shandong Province Centers for Disease Control and Prevention, Sichuan Center for Disease Control and Prevention, Hebei CDC ,China
Conditions
(from sponsor)		 Respiratory Syncytial Virus (RSV)
Enrollment 25,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov